menu

Beyond the Horizon: HELIOS Clinical Trials in ATTR Cardiomyopathy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Beyond the Horizon: HELIOS Clinical Trials in ATTR Cardiomyopathy  

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    The HELIOS trials, a groundbreaking phase 3 program, are investigating the potential of vutrisiran, an RNA interference (RNAi) therapy, to combat both hereditary and wild-type ATTR amyloidosis. Building on a successful phase 1 study demonstrating vutrisiran's safety and effectiveness in reducing serum TTR, HELIOS is paving the way for a new era in ATTR treatment.

    Join Dr. Marianna Fontana as she highlights the cardiac exploratory analysis of HELIOS-A and the design of HELIOS-B.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Alnylam Pharmaceuticals, Inc. 

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The HELIOS trials, a groundbreaking phase 3 program, are investigating the potential of vutrisiran, an RNA interference (RNAi) therapy, to combat both hereditary and wild-type ATTR amyloidosis. Building on a successful phase 1 study demonstrating vutrisiran's safety and effectiveness in reducing serum TTR, HELIOS is paving the way for a new era in ATTR treatment.

    Join Dr. Marianna Fontana as she highlights the cardiac exploratory analysis of HELIOS-A and the design of HELIOS-B.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Alnylam Pharmaceuticals, Inc. 

Facebook Comments

Schedule24 May 2024